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Tobacco smoke from a combustible cigarette contains more than 6000 constituents; approximately 150
of these are identiﬁed as toxicants. Technologies that modify the tobacco blend to reduce toxicant emis-
sions have been developed. These include tobacco sheet substitute to dilute toxicants in smoke and blend
treated tobacco to reduce the levels of nitrogenous precursors and some polyphenols. Filter additives to
reduce gas (vapour) phase constituents have also been developed. In this study, both tobacco blend and
ﬁlter technologies were combined into an experimental cigarette and smoked to International Organisa-
tion on Standardisation and Health Canada pufﬁng parameters. The resulting particulate matter was sub-
jected to a battery of in vitro genotoxicity and cytotoxicity assays – the Ames test, mouse lymphoma
assay, the in vitromicronucleus test and the Neutral Red Uptake assay. The results indicate that cigarettes
containing toxicant reducing technologies may be developed without observing new additional genotoxic
hazards as assessed by the assays speciﬁed. In addition, reductions in bacterial mutagenicity and mam-
malian genotoxicity of the experimental cigarette were observed relative to the control cigarettes. There
were no signiﬁcant differences in cytotoxicity relative to the control cigarettes.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under theCCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction Rodgman, 2013) and approximately 150 of these have been identi-Tobacco smoke from a combustible cigarette is a complex and
dynamic mixture of more than 6000 chemicals (Perfetti andﬁed as toxicants (Fowles and Dybing, 2003). The Institute of Med-
icine (IOM) have reported that smoking related diseases are dose
related and epidemiology demonstrates a reduction in disease inci-
dence following smoking cessation (Stratton et al., 2001). There-
fore it is postulated that it may be possible to reduce smoking
related diseases by reducing toxicant levels in cigarettes
(Stratton et al., 2001). Novel cigarettes with reduced toxicant levels
have been termed potential reduced-exposure products (PREPs)
(Stratton et al., 2001). Strategies for the assessment of modiﬁed
tobacco products, or PREPs, have been published (Life Sciences
Research Ofﬁce, 2007; World Health Organisation, 2007), with
the goal of lowering mainstream smoke (MSS) yields for speciﬁc
smoke toxicants and biomonitoring populations (Burns et al.,
2008; Baker, 1999; Hatsukami et al., 2012).
The Food and Drug Administration (FDA) have introduced the
term ‘modiﬁed risk tobacco products’ (MRTPs). Similar to PREPs,
MRTPs are deﬁned as any tobacco product that is sold or distrib-
uted for use to reduce harm or the risk of tobacco-related disease
and this must be demonstrated by scientiﬁc evidence, including
in vitro systems, models of disease and biomarkers of exposure.
Technologies to reduce toxicant emissions from a cigarette
mainly focus on modifying the tobacco blend or the ﬁlter. Two
blend technologies have been described previously; blend treated
tobacco (BTT) by Liu et al., 2011 and tobacco sheet substitute
Table 1
Composition of cigarettes used in the study.
PM code Blend Filter Format
3R4F US-style blend CA King size
M4A Flue-cured blend CA King size
EC 50% BT, 15% TSS,
35% lamina & DIET
Polymer derived
activated charcoal, CR20L,
ST and CA
Demi-slim
CC US-style blend CA King size
BC 65% BT feedstock,
10% DIET, 25% lamina
CA King size
CA, cellulose acetate; BT, blend treated tobacco; TSS, tobacco sheet substitute; ST,
split tipping; DIET, Dry Ice Expanded Tobacco (tobacco that has been expanded with
dry ice to increase tobacco ﬁlling capacity).
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extraction of tobacco with water followed by protease treatment
and adsorbents, resulting in tobacco with reduced amino acid
and protein content (Liu et al., 2011). Proteins and amino acids
are known precursors for a number of toxicants in smoke, includ-
ing aromatic and heterocyclic amines that contribute to mutage-
nicity (Clapp et al., 1999; Matsumoto and Yoshida, 1981;
Matsushima et al., 1999; Mizusaki et al., 1977). Therefore the
BTT process could potentially reduce the toxicity proﬁle of the
cigarette.
TSS contains high levels of glycerol and calcium carbonate and
when used as a cigarette blend component it reduces the organic
content of tobacco. The glycerol contained in TSS distils into the
MSS during the combustion process, diluting the tar, reducing
the level of a wide range of smoke constituents and the potential
toxicity of cigarettes (McAdam et al., 2011).
Activated charcoal, usually manufactured from coconut shells,
is often used in conventional cigarette ﬁlters to remove volatile
organic compounds (Branton and Bradley, 2011). Polymer derived
activated charcoals demonstrate increased adsorption of volatile
organic compounds, approximately twice as efﬁcient as standard
activated charcoal (Branton et al., 2011a). Another ﬁlter technol-
ogy, CR20L – an amine-functionalised resin bead – has been
described previously by Branton et al., 2011b. In comparison to
standard activated charcoal, it offers superior reductions in formal-
dehyde, hydrogen cyanide and acetaldehyde. Polymer derived acti-
vated charcoals and CR20L, when contained in the ﬁlters of novel
cigarettes, may reduce key toxicants that drive mutagenicity and
cytotoxicity.
Split tipping (ST), a novel method of ﬁlter ventilation, is a gap
between two separated sections of tipping paper, exposing an area
of the ﬁlter. The gap is wrapped with a bespoke paper that is more
porous than standard tipping paper, allowing the diffusion of gases
and vapours into and out of the ﬁlter. ST maintains the ventilation
level at higher ﬂow levels generally encountered when consumers
smoke cigarettes (Dittrich et al., 2014).
Another important aspect of PREPs and MRTPs is the consumer
acceptability of cigarettes that have lower toxicant yields, as they
oftenhaveadifferent smokingexperience compared to conventional
cigarettes. Although the initial acceptability of the experimental cig-
arette used in this studywas lower than the commercial control cig-
arette, the sensory perception of the experimental cigarette changed
over the duration of the study toward a level of acceptability similar
to that of the commercial control (Dittrich et al., 2014).
Studies have shown that humans smoke cigarettes with higher
intensity when compared to laboratory smoking machines oper-
ated to International Organisation for Standardisation (ISO) condi-
tions. Therefore the ISO regime, used as a tobacco industry
standard, may not be representative of human smoking
(Hatsukami et al., 2012). It has also been reported that MSS constit-
uent yields are different under intense regimes when compared to
ISO smoking conditions. As one smoking regime does not represent
the smoking behaviour of humans, it is generally considered that
the ISO and the more intense Health Canada (HCI) regimes are
two extremes of smoking behaviour (St. Charles et al., 2010).
Therefore, particulate matter (PM) generated to ISO and HCI smok-
ing regimes were included in this study.
Several guidelines such as those developed by the International
Conference on Harmonisation (ICH, 2011) and Committee on
Mutagenicity (COM, 2011) recommend a battery of core in vitro
genotoxicity assays for the detection of mutagenicity and potential
for carcinogenicity. For tobacco products, Health Canada also spec-
iﬁes the Neutral Red Uptake assay (NRU) in addition to the Ames
test and the in vitro micronucleus assay (MNvit) (Canada, 2000).
Furthermore, the Cooperation Centre for Scientiﬁc Research
Relative to Tobacco (CORESTA) in vitro Toxicology Task Forcerecommends the Ames test, the MNvit, the mouse lymphoma assay
(MLA) and the NRU (CORESTA, 2004).
This paper describes the in vitro assessment of the genotoxicity
and cytotoxicity of the particulate matter generated from experi-
mental cigarettes (ECs) incorporating 50% BTT, 15% TSS, polymer
derived activated charcoal, CR20L and split tipping technologies
as described above, in a demi-slim format (Table 1) (Dittrich
et al., 2014). The blend technologies described have previously
been tested singularly (McAdam et al., 2011; Liu et al., 2011;
Combes et al., 2012, 2013), but not in combination as described
herein. The particulate matter generated from commercial and
baseline control cigarettes were included as comparator products.
The control cigarettes contained a standard cellulose acetate ﬁlter,
tipping paper and typical tobacco blends however, the baseline
control contained 65% of the BTT feedstock (i.e. the BTT tobacco
without water extraction, enzyme and adsorbent treatment).
3R4F and M4A (US style blended and a ﬂue cured product, respec-
tively) were also included for comparison to historical data. The
experimental and control cigarettes used in this study had an ISO
tar yield of 7 mg per cigarette. Mainstream smoke particulate mat-
ter generated under ISO and HCI pufﬁng parameters from refer-
ence, experimental and control cigarettes were tested using a
battery of in vitro toxicity assays – the Ames test, MLA, MNvit
and NRU.2. Materials & methods
2.1. Cigarettes
Cigarette speciﬁcations are detailed in Table 1, and also in
(Dittrich et al., 2014). 3R4F and M4A were reference cigarettes
and are included in all British American Tobacco (BAT) in vitro
studies to demonstrate the assay performance was comparable to
historic data. A commercial control (CC) and a baseline control
(BC) cigarette were included, containing conventional cigarette
materials. EC was the experimental cigarette containing the blend
and ﬁlter technologies. 3R4F were supplied by the University of
Kentucky and all other cigarettes were manufactured by BAT.2.2. PM generation
Cigarettes were conditioned to ISO 3402 (ISO, 1999) and
smoked on a Borgwaldt RM200s (Borgwaldt-KC, Hamburg, Ger-
many) machine using ISO 3308 (ISO, 2000b, 35 mL puff volume,
of 2 s duration, every 60 s, 0% vent blocking) and Health Canada
(Canada, 2000, 55 mL puff volume, of 2 s duration, every 30 s,
100% vent blocking) pufﬁng parameters. Approximately 6220 mg
PM was collected onto each 44 mm Cambridge ﬁlter pad (CFP)
(Whatman, Maidstone, UK). Pads were weighed pre and post
smoking, to determine the mass of PM deposited. 1/4 of each pad
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Aldrich, Poole, UK) for nicotine, water and nicotine free dry partic-
ulate matter (NFDPM) determination (ISO, 2000a). PM from the 3/4
pad was eluted with anhydrous dimethyl sulfoxide (DMSO)
(Sigma–Aldrich, Poole, UK) under vacuum to a ﬁnal stock concen-
tration of 24 mg/mL. PM extracts were stored in single-use aliquots
immediately at 80 C. Samples were transported on dry ice to an
independent Good Laboratory Practice (GLP) accredited laboratory
for in vitro testing, where they were stored immediately at 80 C
and used within 12 months. Crooks et al., 2013 have demonstrated
stability of PM when stored at 80 C for up to 2 years. Samples
were blind tested using a suitable coding system.
2.3. In vitro toxicology testing
Aroclor 1254 induced rat liver post-mitochondrial supernatant
(S9) mix (Moltox™, North Carolina, USA) provided metabolic acti-
vation in the genotoxicity assays, where speciﬁed. Appropriate
positive and vehicle controls were included in all experiments, as
recommended by the relevant guidelines. All chemicals were
obtained from Sigma–Aldrich, Poole, UK, unless otherwise stated.
2.3.1. Ames test
Five tester strains of Salmonella typhimurium TA98, TA1535,
TA1537 (obtained from UK National Collection of Type Cultures),
TA100 and TA102 (derived from Covance Laboratories Inc., Vienna,
USA) were used in the presence and absence of S9 in accordance
with Organisation for Economic and Cooperative Development
(OECD) Test Guideline 471 (OECD, 1997a). At least eight PM con-
centrations per cigarette type were used per experiment. Four
independent repeat plate incorporation tests and one pre-incuba-
tion test were performed. With tester strains TA98, TA100 and
TA1537 +S9, ﬁve, four and ten replicate plates, respectively, were
used per concentration in all experiments as recommended by
Scott et al., 2013. The remaining strains and treatment conditions
used three replicate plates.
2.3.2. MLA
The MLA was performed using L5178Y tk+/ cells (Burroughs
Wellcome Co., London, UK) cultured in supplemented Roswell Park
Memorial Institute Medium (RPMI). Ten concentrations were
tested with four replicates cultures per concentration. Two inde-
pendent repeat experiments were performed, each using a 3 h
+S9, 3 and 24 h –S9 exposures. After a 2 days expression period,
cells were grown for 8 days and triﬂouro-thymidine (TFT) resistant
colonies were counted and the percent relative total growth (RTG)
determined. PMs that exceeded the Global Evaluation Factor (GEF)
(plus vehicle control) were considered mutagenic. This method
complied with OECD Test Guideline 476 (OECD, 1997b).Fig. 1. Bacterial mutagenicity of particulate matter generated from the experimental ciga
the ISO (A) and HCI (B) regimes. Data presented as the mean of four independent plate2.3.3. MNvit
Four replicate V79 (University of Swansea, UK) cell cultures in
Dulbecco’s Modiﬁed Eagles Medium (DMEM) supplemented with
10% Foetal Calf Serum (FCS) and 0.52% penicillin/streptomycin
were treated with PM for 3 h followed by a 21 h recovery ±S9, or
treated for 24 h S9 with no recovery period. Cytochalasin B, for-
mulated in DMSO, was added to all treatment ﬂasks at the time
of treatment at a ﬁnal concentration of 3 lg/mL. At least four con-
centrations were tested for each PM and scored for cytotoxicity
and micronucleated binucleate cells (MNBN) on quadruplicate
slides and 2000 cells per slide were analysed. This method com-
plied with OECD Test Guideline 487 (OECD, 2010).2.3.4. NRU
Balb/c 3T3 clone A31 mouse ﬁbroblasts (European Collection of
Cell Cultures) were maintained in DMEM supplemented with 10%
(v/v) FCS, 4 mM L-glutamine and penicillin/streptomycin (1% v/v).
Cytotoxicity was expressed as a reduction in the uptake of Neutral
Red dye into the lysosomes of cells after a 24 h culture, measured
by absorbance at 450 nm. A minimum of six concentrations were
tested for each PM, to determine concentration-dependent inhibi-
tion of cell growth. Six wells per concentration were used for each
PM, vehicle or positive control (sodium dodecyl sulphate). This
protocol conforms to the guidelines issued by the National Insti-
tute of Health (NIH, 2001). Four independent repeat experiments
were performed.2.3.5. Statistical analysis
The concentration–response of each PM in the genotoxicity
assays were assessed for signiﬁcance above the vehicle control.
The Ames test was analysed with Dunnett’s test; the MLA used
weighted regression (Robinson et al., 1989); and the MNvit used
Fisher’s Exact Test (Richardson et al., 1989).
PMs were compared according to the recommendations of Scott
et al., 2013. For the genotoxicity assays, the linear portion of the
concentration response curve was identiﬁed by ﬁtting a general-
ised linear model, using adaptations to accommodate the log-nor-
mal, binomial and Poisson distributions of the MLA, MNvit and
Ames test, respectively. The slopes of the two PMs being compared
were tested for parallelism and if signiﬁcant, there was a statistical
difference in slopes. If non-signiﬁcant, the magnitudes of the two
PMs were compared. If linearity was not identiﬁed, pairwise com-
parisons were made using t-tests at each common concentration.
All tests were performed with two sided risk.
For the NRU, the PM concentration causing 50% toxicity (IC50)
was calculated by ﬁtting a four parameter logistic model to the
percentage survival. Pairwise comparisons of the log-transformed
IC50 estimates were made using a two-sample t-test.rette (), commercial (h) and baseline (4) controls in TA98 in the presence of S9 at
incorporation experiments ± SEM.
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3.1. Reference products
The particulate matter generated at ISO and HCI pufﬁng param-
eters demonstrated that the ﬂue cured product, M4A, was less
mutagenic than the American-blended product, 3R4F in the Ames
test. In the MLA, MNvit and NRU, M4A was more active than
3R4F. This data was consistent with the historical datasets for
these products generated under ISO conditions.3.2. Ames test
In the Ames test, all particulate matters were non-mutagenic in
all tester strains S9, and in strain TA1535 +S9. Some increases in
revertants in tester strain TA102 +S9 were observed, but this was
only seen in one experiment with no more than a 1.4-fold increase
in revertants above the vehicle control and did not demonstrate
concentration related increases. Consistent and reproducible
mutagenic activity was detected in strains TA98, TA100 and
TA1537, all in the presence of S9 only, with the exception of the
commercial and baseline control particulate matters generated
under the Health Canada regime in strain TA100 +S9 in one exper-
iment, where the particulate matter concentration revertant colo-
nies did not exceed those of the vehicle control; this data was
excluded from comparative analysis.
In tester strain TA98 in the presence of S9, the experimental cig-
arette was less mutagenic than the commercial control particulate
matter generated to ISO, however the mutagenicity of the experi-
mental cigarette was equivalent to the baseline control (Fig. 1A
and Table 2). At the HCI regime, the experimental cigarette was
less mutagenic than the commercial and baseline controls
(Fig. 1B and Table 2).
In TA100 in the presence of S9, the experimental cigarette was
less mutagenic than the commercial and baseline controls at both
smoking regimes (Fig. 2 and Table 2).
In strain TA1537 +S9, variable results were obtained. The partic-
ulate matter generated from the experimental cigarette generated
under the HCI regime showed overall reduced mutagenicity com-
pared to the commercial control generated under the same condi-
tions and equivalent mutagenic activity relative to the baseline
control (Fig. 3B and Table 2). The particulate matter generated to
the ISO regime demonstrated that the experimental cigaretteTable 2
Relative mutagenicity of the experimental cigarette (EC) compared to the commercial (CC)
TA100 and TA1537 +S9 for each individual experiment. Grey boxes indicate where product A
baseline control). White boxes indicate where product A was more active than product B.particulate matter was more mutagenic than the baseline control
(Fig. 3A and Table 2). However, relative to the commercial control,
the two products were equivalent (Fig. 3A and Table 2).
3.3. MLA
All particulate matters in all treatment conditions induced con-
centration related increases in cytotoxicity to approximately 20%
RTG. In addition, statistically signiﬁcant increases in mutation fre-
quency were observed and all particulate matters exceeded the
GEF plus vehicle control.
The experimental cigarette was less genotoxic relative to the
commercial control in the 3 h treatments both in the absence
and presence of S9 (Figs. 4A, 5A and Table 3) at the ISO regime.
However, there was no difference between the experimental ciga-
rette and the commercial control particulate matters generated to
the HCI regimes (Figs. 4A, 5A and Table 3).
Comparison with the baseline control particulate matter gener-
ated to the ISO regime, the experimental cigarettewas of equivalent
genotoxic potential in the 3 h treatments in the presence and
absence of S9 (Figs. 4A, 5A and Table 3). However, under the HCI
regime, the experimental cigarette was less genotoxic than the
baseline control in the 3 h S9 (Fig. 4B) and +S9 treatments
(Table 3).
In the 24 h treatment, the experimental cigarette was of equiv-
alent mutagenicity to the commercial control under the ISO
(Fig. 5B and Table 3) and HCI regimes. Relative to the baseline con-
trol, the experimental cigarette was less mutagenic at the ISO
regime (Fig. 5B and Table 3). At the HCI regime, there were no dif-
ferences between the experimental and baseline cigarettes
(Table 3).
3.4. MNvit
In the MNvit, all particulate matters in all treatment conditions
induced concentration related increases in cytotoxicity to approx-
imately 60%. In addition, statistically signiﬁcant linear trends were
observed in induced MNBN frequency.
Under all treatment conditions, the experimental cigarette par-
ticulate matter generated to ISO conditions was less genotoxic than
the commercial and baseline controls (Fig. 6A and Table 4). The
only exception to this was observed in the 3 h +S9 treatment,
where the experimental cigarette was more mutagenic than the
commercial control (Table 4). However, under the HCI regime, inand baseline (BC) controls at the ISO and HCI smoking regimes in tester stains TA98,
(i.e. the experimental cigarette) was less active than product B (i.e. the commercial or
Fig. 2. Bacterial mutagenicity of particulate matter generated from the experimental cigarette (), commercial (h) and baseline (4) controls in TA100 in the presence of S9 at
the ISO (A) and HCI (B) smoking regimes. Data presented as the mean of four (ISO) and three (HCI) independent plate incorporation tests ± SEM.
Fig. 5. Genotoxicity (mutation frequency per 106 viable cells) of particulate matter generated to the ISO smoking regime from the experimental cigarette (), commercial (h)
and baseline (4) controls as assessed in the mouse lymphoma assay for 3 h +S9 (A) and 24 h S9 (B). Data shown is the mean of two independent experiments ± SEM.
Fig. 3. Bacterial mutagenicity of the particulate matter generated from experimental cigarette (), commercial (h) and baseline (4) controls in TA1537 +S9 at the ISO (A) and
HCI (B) regime. Data presented as the mean of four independent plate incorporation tests ± SEM.
Fig. 4. Genotoxicity (mutation frequency per 106 viable cells) of particulate matter generated to the ISO (A) and HCI (B) smoking regimes from the experimental cigarette (),
commercial (h) and baseline (4) controls as assessed in the mouse lymphoma assay for 3 h S9. Data shown is the mean of two independent experiments ± SEM.
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Table 3
Relative genotoxicity of the experimental cigarette (EC) compared to the commercial (CC) and baseline (BC) controls at the ISO and HCI smoking regimes in the mouse lymphoma
assay for each individual experiment. Grey boxes indicate where product A (i.e. the experimental cigarette) was less active than product B (i.e. the commercial or baseline
control). White boxes indicate where product A was more active than product B.
Fig. 6. Genotoxicity of particulate matter generated to the ISO (A) and HCI (B) smoking regimes from the experimental cigarette (), commercial (h) and baseline (4) controls
as assessed in the in vitro micronucleus test with V79 cells for 24 hours S9. Micronucleated binucleate cells are per 2000 cells analysed. Data shown is the mean of four
replicate cultures ± SD.
Table 5
IC50 (lg/mL) values obtained in the NRU assay from the experimental cigarette (EC),
commercial (CC) and baseline (BC) controls at the ISO and HCI regimes.
ISO HCI
EC 53.86 60.04
CC 54.24 68.91
BC 50.43 60.24
Table 4
Relative genotoxicity of the experimental cigarette (EC) compared to the commercial (CC) and baseline (BC) controls at the ISO and HCI smoking regimes in the in vitro
micronucleus test. Grey boxes indicate where product A (i.e. the experimental cigarette) was less active than product B (i.e. the commercial or baseline control). White boxes
indicate where product A was more active than product B.
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cigarette was less active than the commercial and baseline controls
(Fig. 6B and Table 4). In the 3 h S9 treatment, the experimental
cigarette was equivalent to the commercial and baseline controls
(Table 4).
3.5. NRU
In the Neutral Red Uptake assay, although there were some
small differences in the calculated IC50 values, there were no signif-
icant differences between the experimental cigarette and the base-
line and commercial controls at either smoking regime (Table 5).4. Discussion
The potential of BTT, TSS and ﬁlter additives to reduce the
mutagenicity and genotoxicity of the particulate matter from an
experimental cigarette was investigated. These blend technologies
have previously been described and tested in vitro individually
however, they have not been tested in combination. The ﬁlter addi-
tives will also reduce the level of volatile compounds in the main-stream smoke of the experimental cigarette, which is further
enhanced by the TSS diluent technology (McAdam et al., 2011).
The cigarette smoke particulate matter tested was used as it has
a history of use, is easily collected, multiple doses can be tested and
produces consistent results (Wan et al., 2009). Other exposure
methods are available that are more physiologically relevant and
also take into consideration the gas (vapour) phase of the main-
stream smoke aerosol, rather than the particulate in isolation.
However, these whole smoke exposure systems are being devel-
oped and optimised for the toxicological assessment of cigarette
smoke aerosols and are currently not standardised (Aufderheide
et al., 2003; Thorne and Adamson, 2013; Wan et al., 2009).
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strains TA98 and TA100 +S9 and the in vitro micronucleus test,
the experimental cigarette containing the toxicant reducing tech-
nologies was less mutagenic than the commercial and baseline
control at both smoking regimes, in the majority of comparisons
made. The differences were generally small, ranging between 8%
and 30% in the Ames test and 6–33% in the MNvit relative to the
commercial or baseline control responses. There were some
instances, particularly in the Ames test with tester strain TA1537
and the MLA where, although reduced mutagenicity and genotox-
icity of the experimental cigarette was sometimes observed, inter-
experimental variation was large or the differences were not of sta-
tistical signiﬁcance (Tables 2–4). The variability observed in
TA1537 (Table 2) could be attributed to tester strain characteristics
between the two strains that detect frame-shift mutagens, TA98
and TA1537. Strain TA98 contains a plasmid (pKM101) that codes
for error prone DNA repair mechanisms (Maron and Ames, 1983;
McMahon et al., 1979), whereas TA1537 has normal DNA repair
mechanisms. This potentially helps explain enhanced differentia-
tion between experimental cigarettes containing toxicant reducing
technologies in TA98, compared to TA1537.
Furthermore, the variability could be due to the robust statisti-
cal methods applied to this study (Scott et al., 2013), including the
increase in replicates used per concentration, which was designed
to enhance the discriminatory ability of the assays. However,
reductions in the MLA and MNvit were not expected, based on
the inclusion levels of BTT and TSS in the experimental cigarette
described here. Compared to the previous individually tested blend
technologies (Combes et al., 2012, 2013; McAdam et al., 2011; Liu
et al., 2011), the inclusion level of BTT and TSS appear to be at the
threshold to observe biological effects. This is consistent with pre-
viously published data, where Combes et al., 2012 concluded that
experimental cigarettes containing 40% BTT were not different to
their respective controls. In Combes et al. (2013), experimental cig-
arettes containing 20% TSS had small reductions in the NRU and
MLA in the absence of S9, but did not affect the Ames or MNvit.
However, in this study, the combination of BTT and TSS are
included at levels where in previous publications no differences
were observed (Combes et al., 2012, 2013; McAdam et al., 2011;
Liu et al., 2011), appear to have effectively reduced mutagenicity
in some Ames strains, and in the MLA and MNvit, without affecting
cytotoxicity as assessed by the NRU.
These results are consistent with the BTT process removing
more than half of the protein nitrogen, and more than 40% of the
total polyphenols (Liu et al., 2011). The considerable reduction in
protein nitrogen resulted in the generation of lower levels of aro-
matic and heterocyclic amine protein products generated on smok-
ing, considered to be the main contributor to mutagenicity (Clapp
et al., 1999; Matsumoto and Yoshida, 1981; Matsushima et al.,
1999; Mizusaki et al., 1977). The addition of the TSS to effectively
dilute the MSS, has further enhanced the reductions achieved by
BTT (McAdam et al., 2011). Further testing on the whole smoke
aerosol could be warranted when exposure techniques become
standardised and widely used. This would allow the in vitro toxico-
logical evaluation of the smoke aerosol in its native form, including
the gas (vapour) phase, rather than the particulate matter in isola-
tion (Ritter et al., 2004; Thorne et al., 2013, 2014). This is of critical
importance, as ﬁlter additives do not affect particulate matter col-
lected on a CFP (Baker, 1999) and therefore the vapour phase
effects were not assessed in this study.
In conclusion, these data indicate that combining BTT and TSS
have the potential to reduce the mutagenicity and genotoxicity
of the particulate matter derived from the experimental cigarette,
without affecting its cytotoxic potential. Furthermore, the incorpo-
ration of these technologies do not add to the genotoxic potential,nor are new genotoxic hazards observed, as assessed by the assays
used herein. While in vitro tests alone cannot predict risk, they con-
tribute to a weight of evidence paradigm for the risk assessment of
reduced toxicant prototype cigarettes. Together with smoke com-
position, biomarkers of exposure and biological effect, urine muta-
genicity and smoking behaviour data, in vitro genotoxicity and
cytotoxicity studies can help to evaluate the biological signiﬁcance
of exposure to tobacco smoke toxicants.
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